Goldman Sachs Raises INNOVENT BIO's Profit Forecasts, Maintains Buy Rating with HK$102.85 Target

Stock News

Yesterday

Goldman Sachs has issued a research report updating its earnings per share forecast for INNOVENT BIO (01801). The bank raised its projections for 2025 to 2027 from RMB 0.54, RMB 1.43, and RMB 2.49 to RMB 0.62, RMB 1.74, and RMB 2.54, respectively. The target price was set at HK$102.85, down from HK$107.96 previously, while maintaining a "Buy" rating. INNOVENT BIO reported fourth-quarter product revenue of approximately RMB 3.3 billion, meeting expectations. This represented a 60% year-over-year increase from a relatively low base, with sequential performance remaining flat. The results were affected by channel rebates linked to price reductions in the 2026 National Reimbursement Drug List. The company's new product portfolio maintained growth momentum, increasing 13% quarter-over-quarter and offsetting weaker performance from Tyvyt. Full-year 2025 product sales were strong, rising 45% year-over-year to RMB 11.9 billion, marking the first time the company surpassed the RMB 10 billion milestone. The conventional biologics business served as the primary growth driver.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1107483307"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1107483307\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1107483307?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-06 11:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1107483307","market":"fut","top_or_hot":-1,"title":"Goldman Sachs Raises INNOVENT BIO's Profit Forecasts, Maintains Buy Rating with HK$102.85 Target","media":"Stock News","content":"<p>Goldman Sachs has issued a research report updating its earnings per share forecast for INNOVENT BIO (01801). The bank raised its projections for 2025 to 2027 from RMB 0.54, RMB 1.43, and RMB 2.49 to RMB 0.62, RMB 1.74, and RMB 2.54, respectively. The target price was set at HK$102.85, down from HK$107.96 previously, while maintaining a \"Buy\" rating. INNOVENT BIO reported fourth-quarter product revenue of approximately RMB 3.3 billion, meeting expectations. This represented a 60% year-over-year increase from a relatively low base, with sequential performance remaining flat. The results were affected by channel rebates linked to price reductions in the 2026 National Reimbursement Drug List. The company's new product portfolio maintained growth momentum, increasing 13% quarter-over-quarter and offsetting weaker performance from Tyvyt. Full-year 2025 product sales were strong, rising 45% year-over-year to RMB 11.9 billion, marking the first time the company surpassed the RMB 10 billion milestone. The conventional biologics business served as the primary growth driver.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Goldman Sachs Raises INNOVENT BIO's Profit Forecasts, Maintains Buy Rating with HK$102.85 Target</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGoldman Sachs Raises INNOVENT BIO's Profit Forecasts, Maintains Buy Rating with HK$102.85 Target\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-02-06 11:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Goldman Sachs has issued a research report updating its earnings per share forecast for INNOVENT BIO (01801). The bank raised its projections for 2025 to 2027 from RMB 0.54, RMB 1.43, and RMB 2.49 to RMB 0.62, RMB 1.74, and RMB 2.54, respectively. The target price was set at HK$102.85, down from HK$107.96 previously, while maintaining a \"Buy\" rating. INNOVENT BIO reported fourth-quarter product revenue of approximately RMB 3.3 billion, meeting expectations. This represented a 60% year-over-year increase from a relatively low base, with sequential performance remaining flat. The results were affected by channel rebates linked to price reductions in the 2026 National Reimbursement Drug List. The company's new product portfolio maintained growth momentum, increasing 13% quarter-over-quarter and offsetting weaker performance from Tyvyt. Full-year 2025 product sales were strong, rising 45% year-over-year to RMB 11.9 billion, marking the first time the company surpassed the RMB 10 billion milestone. The conventional biologics business served as the primary growth driver.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HK0000165453.HKD","symbol_name":"华夏精选大中华科技基金 A类港币","start_time":0,"source_url":"","article_id":"1107483307","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1107483307","pubTimestamp":1770346819,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Goldman Sachs has issued a research report updating its earnings per share forecast for INNOVENT BIO (01801). The bank raised its projections for 2025 to 2027 from RMB 0.54, RMB 1.43, and RMB 2.49 to...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","BK1161":"生物科技","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","LU0455707207.USD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (USD) INC","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD","BK1583":"高瓴概念","LU0502904849.HKD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (HKD) ACC","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","BK1589":"北水核心资产","01801":"信达生物","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC"},"translate_title":"高盛上调信达生物盈利预测维持买入评级目标102.85港元","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01801":1},"content_text":"Goldman Sachs has issued a research report updating its earnings per share forecast for INNOVENT BIO (01801). The bank raised its projections for 2025 to 2027 from RMB 0.54, RMB 1.43, and RMB 2.49 to RMB 0.62, RMB 1.74, and RMB 2.54, respectively. The target price was set at HK$102.85, down from HK$107.96 previously, while maintaining a \"Buy\" rating. INNOVENT BIO reported fourth-quarter product revenue of approximately RMB 3.3 billion, meeting expectations. This represented a 60% year-over-year increase from a relatively low base, with sequential performance remaining flat. The results were affected by channel rebates linked to price reductions in the 2026 National Reimbursement Drug List. The company's new product portfolio maintained growth momentum, increasing 13% quarter-over-quarter and offsetting weaker performance from Tyvyt. Full-year 2025 product sales were strong, rising 45% year-over-year to RMB 11.9 billion, marking the first time the company surpassed the RMB 10 billion milestone. The conventional biologics business served as the primary growth driver.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}